A WEIBULL DISTRIBUTION MODEL FOR INTRADERMAL ADMINISTRATION OF CEFTAZIDIME

被引:3
作者
BRESSOLLE, F
LAURELLI, JM
GOMENI, R
BECHIER, JG
WYNN, NR
GALTIER, M
ELEDJAM, JJ
机构
[1] CHU NIMES,PHARM CAREMEAU,PHARMACOKINET LAB,NIMES,FRANCE
[2] SIMED,F-94008 CRETEIL,FRANCE
[3] CHU NIMES,DEPT ANESTHESIE REANIMAT,NIMES,FRANCE
[4] FAC PHARM MONTPELLIER,CHIM ANALYT LAB,F-34060 MONTPELLIER,FRANCE
关键词
D O I
10.1002/jps.2600821123
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The pharmacokinetics of 1 g of ceftazidime administered intradermally was studied in seven healthy volunteers. The objective of the present study was to find the most appropriate mathematical model to describe the drug intake process. The concentration of ceftazidime in plasma was measured by HPLC. The disposition of the drug was described by a one-compartment pharmacokinetic model, with drug intake occurring by different processes: a zero-order process due to the administration and a first-order intake from the injection site to the systemic circulation. The Weibull model was considered as an approximation of the overall process. The mean Weibull parameters were td (time necessary to transfer 63% of the administered drug into the systemic circulation) of 2.75 +/- 0.75 h, and f (shape) of 1.04 +/- 0.15. The mean elimination half-life was 2.0 +/- 0.4 h. The area under the concentration versus time curve obtained in this study (139 +/- 46 mg . h/L) is very near to literature values reported after single intravenous doses of 1 g of ceftazidime, suggesting that the bioavailability of ceftazidime after intradermal administration may be approximately 100%. Moreover, the mean peak plasma concentration (37 +/- 16 mg/L) is in the same range as that reported in the literature after intramuscular administration of a single dose of 1 g.
引用
收藏
页码:1175 / 1178
页数:4
相关论文
共 16 条
[2]   DISTRIBUTION OF CEFTAZIDIME IN ASCITIC FLUID [J].
BENONI, G ;
AROSIO, E ;
RAIMONDI, MG ;
APOLLONI, E ;
PASSARELLA, E ;
LECHI, A ;
VELO, GP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1984, 25 (06) :760-763
[3]  
BINAGLIA L, 1981, J MESOTERAPIA, V1, P9
[4]  
CORBEL D, 1989, B ACAD NAT MED PARIS, V173, P223
[5]   CEFTAZIDIME - THERAPEUTIC RESULTS IN VARIOUS INFECTIONS AND KINETIC-STUDIES [J].
DAIKOS, GK ;
KOSMIDIS, J ;
STATHAKIS, C ;
GIAMARELLOU, H ;
DOUZINAS, E ;
KASTANAKIS, S ;
PAPATHANASSIOU, B .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1981, 8 :331-337
[6]  
DAIKOS GK, 1982, CURRENT CHEMOTHERAPY, P499
[7]  
GOMENI C, 1987, 7TH P INT C MED INF, P507
[8]   THE COMPARATIVE PHARMACOKINETICS OF CEFTAZIDIME AND CEFOTAXIME IN HEALTHY-VOLUNTEERS [J].
HARDING, SM ;
MONRO, AJ ;
THORNTON, JE ;
AYRTON, J ;
HOGG, MIJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1981, 8 :263-272
[9]   PHARMACOKINETICS OF CEFTAZIDIME IN NORMAL AND UREMIC SUBJECTS [J].
LEROY, A ;
LEGUY, F ;
BORSA, F ;
SPENCER, GR ;
FILLASTRE, JP ;
HUMBERT, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1984, 25 (05) :638-642
[10]   PHARMACOKINETICS AND BIOAVAILABILITY OF INJECTED GLUCAGON - DIFFERENCES BETWEEN INTRAMUSCULAR, SUBCUTANEOUS, AND INTRAVENOUS ADMINISTRATION [J].
MUHLHAUSER, I ;
KOCH, J ;
BERGER, M .
DIABETES CARE, 1985, 8 (01) :39-42